Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cambrex Investing $3.6M at Sweden Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cambrex Investing $3.6M at Sweden Facility

To increase flexible drug substance manufacturing capacity by 25%.

By: Contract Pharma

Contract Pharma Staff

Cambrex is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity. The work, which will convert a previously customer-dedicated manufacturing train, will include an additional production line at 6 m³ scale, resulting in a 25 percent capacity increase at the facility.

Engineering work began and is expected to be completed by November 2020. The work involves modification of an existing 4 reactor configuration and the installation of new holding tanks and a 4 m2 Hastelloy Rosemund filter.

Cambrex’s site in Karlskoga employs more than 400 people and features a wide range of flexible manufacturing facilities, including 4 cGMP pilot plants and 5 full-scale commercial production units. In 2019, a new 600 m2 process and analytical development facility was added to the site, along with a 3,000 m2 logistics center.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics